Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Growth | Market Cap | Revenue | EBITDA | Earnings | EPS | Rev. Y/Y | Rev. 5Y | Earn. Y/Y | Earn. 5Y | Earnings Date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARGX | ARGENX SE | $35.11B | $4.73M | $114.32M | $905.48M | $15.13 | -88.53% | -44.77% | N/A | N/A | 2025-07-15 | ||
| CRMD | CORMEDIX INC | $987.53M | $82.55M | $17.67M | $17.18M | $0.26 | N/A | 235.70% | N/A | N/A | |||
| GYRE | GYRE THERAPEUTICS INC | $749.12M | $100.64M | $13.36M | $7.25M | $0.08 | -13.01% | 43.80% | N/A | N/A | |||
| TGTX | TG THERAPEUTICS INC | $5.72B | $386.39M | $70.41M | $39.15M | $0.27 | 33.54% | 379.77% | -6.90% | N/A | |||
| CORT | CORCEPT THERAPEUTICS INC | $7.43B | $685.45M | $110.98M | $132.49M | $1.27 | 30.93% | 15.40% | 10.43% | 6.66% | 2025-07-28 | ||
| RPRX | ROYALTY PHARMA PLC | $19.59B | $2.26B | $1.34B | $1.09B | $2.47 | 1.13% | 3.78% | 37.99% | N/A | |||
| VCEL | VERICEL CORP | $2.15B | $238.54M | $16.81M | $2.98M | $0.05 | 14.80% | 14.22% | N/A | N/A | |||
| KRYS | KRYSTAL BIOTECH INC | $3.96B | $333.45M | $144.76M | $123.96M | $4.32 | 247.53% | N/A | 118.18% | N/A | |||
| AUPH | AURINIA PHARMACEUTICALS INC | $1.11B | $247.30M | $65.88M | $39.85M | $0.29 | 29.20% | 278.58% | N/A | N/A | |||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $1.89B | $744.85M | $237.95M | $152.72M | $2.67 | 20.62% | N/A | 13.62% | N/A | |||
| HALO | HALOZYME THERAPEUTICS INC | $6.65B | $1.08B | $704.60M | $485.36M | $3.85 | 25.65% | 45.83% | 57.14% | N/A | |||
| CPRX | CATALYST PHARMACEUTICALS INC | $2.87B | $534.65M | $296.55M | $197.35M | $1.65 | 29.97% | 35.05% | 175.00% | 31.48% | |||
| INCY | INCYTE CORP | $13.11B | $4.41B | $406.83M | $21.27M | $0.29 | 17.13% | 14.63% | -91.29% | N/A | 2025-07-28 | ||
| ADMA | ADMA BIOLOGICS INC | $4.97B | $459.38M | $160.80M | $206.77M | $0.88 | 62.22% | 66.39% | N/A | N/A | 2025-08-06 | ||
| MNKD | MANNKIND CORP | $1.13B | $297.60M | $82.59M | $30.12M | $0.10 | 32.50% | 36.93% | 150.00% | N/A | |||
| EXEL | EXELIXIS INC | $11.34B | $2.30B | $894.63M | $643.57M | $2.25 | 24.49% | 18.61% | 251.56% | 18.57% | 2025-08-12 | ||
| NVO | NOVO NORDISK A S | $356.44B | $46.00B | $23.12B | $15.87B | $3.57 | 24.47% | 18.77% | 18.06% | 22.09% | |||
| MDXG | MIMEDX GROUP INC | $892.12M | $352.38M | $63.32M | $40.18M | $0.27 | 5.34% | 3.66% | -48.08% | N/A | 2025-07-29 | ||
| TECH | BIO-TECHNE CORP | $7.92B | $1.21B | $289.57M | $131.67M | $0.83 | 4.72% | 9.88% | -34.65% | -7.46% | |||
| JAZZ | JAZZ PHARMACEUTICALS PLC | $6.69B | $4.06B | $1.25B | $482.20M | $7.79 | 5.76% | 13.18% | 48.95% | 9.63% | |||
| VCYT | VERACYTE INC | $2.07B | $463.39M | $63.03M | $33.05M | $0.43 | 23.42% | 30.60% | N/A | N/A | |||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $10.78B | $2.95B | $777.43M | $523.88M | $2.75 | 19.36% | 10.32% | 152.29% | 33.85% | |||
| NAGE | NIAGEN BIOSCIENCE INC | $1.07B | $107.93M | $16.04M | $14.11M | $0.18 | 29.77% | 16.36% | N/A | N/A | |||
| GMAB | GENMAB A | $15.11B | $3.15B | N/A | $1.11B | $1.73 | 25.31% | 31.74% | 46.37% | 27.07% | |||
| ACAD | ACADIA PHARMACEUTICALS INC | $3.63B | $996.28M | $278.16M | $228.88M | $1.38 | 22.42% | 22.16% | N/A | N/A |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.